Arrail Group Valuation

Is 6639 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6639 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6639 (HK$3.04) is trading below our estimate of fair value (HK$21.04)

Significantly Below Fair Value: 6639 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6639?

Key metric: As 6639 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 6639. This is calculated by dividing 6639's market cap by their current earnings.
What is 6639's PE Ratio?
PE Ratio73.8x
EarningsCN¥17.16m
Market CapCN¥1.27b

Price to Earnings Ratio vs Peers

How does 6639's PE Ratio compare to its peers?

The above table shows the PE ratio for 6639 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average49x
1846 EuroEyes International Eye Clinic
12.6x26.7%HK$1.4b
9960 Kindstar Globalgene Technology
110.5x88.0%HK$1.1b
6667 Mega Genomics
51.8xn/aHK$1.8b
9860 Adicon Holdings
20.9x20.2%HK$5.0b
6639 Arrail Group
73.8xn/aHK$1.4b

Price-To-Earnings vs Peers: 6639 is expensive based on its Price-To-Earnings Ratio (73.8x) compared to the peer average (49x).


Price to Earnings Ratio vs Industry

How does 6639's PE Ratio compare vs other companies in the HK Healthcare Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
574 Pa Shun International Holdings
2.1xn/aUS$9.48m
No more companies available in this PE range
6639 73.8xIndustry Avg. 12.7xNo. of Companies9PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 6639 is expensive based on its Price-To-Earnings Ratio (73.8x) compared to the Hong Kong Healthcare industry average (12.7x).


Price to Earnings Ratio vs Fair Ratio

What is 6639's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6639 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio73.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6639's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6639 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$3.04
HK$9.27
+205.1%
17.8%HK$10.92HK$7.62n/a2
Nov ’25HK$3.33
HK$9.24
+177.5%
17.8%HK$10.89HK$7.60n/a2
Oct ’25HK$4.35
HK$9.24
+112.4%
17.8%HK$10.89HK$7.60n/a2
Sep ’25HK$3.66
HK$9.24
+152.5%
17.8%HK$10.89HK$7.60n/a2
Aug ’25HK$4.00
HK$8.12
+103.0%
24.0%HK$10.75HK$6.10n/a3
Jul ’25HK$5.18
HK$9.40
+81.5%
12.4%HK$10.80HK$7.95n/a3
Jun ’25HK$6.00
HK$9.39
+56.5%
11.8%HK$10.70HK$7.98n/a3
May ’25HK$6.27
HK$9.39
+49.8%
11.8%HK$10.70HK$7.98n/a3
Apr ’25HK$6.51
HK$9.39
+44.2%
11.8%HK$10.70HK$7.98n/a3
Mar ’25HK$6.05
HK$10.64
+75.8%
8.2%HK$11.60HK$9.50n/a3
Feb ’25HK$6.10
HK$10.64
+74.4%
8.2%HK$11.60HK$9.50n/a3
Jan ’25HK$7.18
HK$10.64
+48.1%
8.2%HK$11.60HK$9.50n/a3
Dec ’24HK$7.29
HK$10.64
+45.9%
8.2%HK$11.60HK$9.50n/a3
Nov ’24HK$7.77
HK$11.04
+42.1%
14.0%HK$12.58HK$9.50HK$3.332
Oct ’24HK$7.74
HK$11.04
+42.7%
14.0%HK$12.58HK$9.50HK$4.352
Sep ’24HK$8.06
HK$11.43
+41.8%
12.6%HK$12.87HK$10.00HK$3.662
Aug ’24HK$8.53
HK$11.43
+34.0%
12.6%HK$12.87HK$10.00HK$4.002
Jul ’24HK$7.51
HK$11.80
+57.1%
7.7%HK$12.71HK$10.89HK$5.182
Jun ’24HK$7.30
HK$13.25
+81.5%
16.6%HK$15.45HK$11.05HK$6.002
May ’24HK$10.78
HK$13.25
+22.9%
16.6%HK$15.45HK$11.05HK$6.272
Apr ’24HK$14.52
HK$14.02
-3.5%
15.2%HK$15.66HK$11.01HK$6.513
Mar ’24n/a
HK$14.02
0%
15.2%HK$15.66HK$11.01HK$6.053
Feb ’24n/a
HK$12.81
0%
21.0%HK$14.84HK$9.00HK$6.103
Jan ’24n/a
HK$12.81
0%
21.0%HK$14.84HK$9.00HK$7.183
Dec ’23n/a
HK$12.81
0%
21.0%HK$14.84HK$9.00HK$7.293
Nov ’23n/a
HK$12.81
0%
21.0%HK$14.84HK$9.00HK$7.773

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies